Home › ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data...
 

Keywords :   


ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data...

2014-06-01 18:26:53| Logistics - Topix.net

ImmunoGen, Inc. , a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced the presentation of favorable clinical findings with SAR3419 from the STARLYTE Phase II trial in diffuse large B-cell lymphoma .

Tags: data phase clinical favorable

Category:Transportation and Logistics

Latest from this category

All news
17.11Summary for Tropical Storm Sara (AT4/AL192024)
17.11Tropical Storm Sara Public Advisory Number 13A
17.11Tropical Storm Sara Graphics
17.11Eastern North Pacific Tropical Weather Outlook
17.11Atlantic Tropical Weather Outlook
16.11Tropical Storm Sara Graphics
16.11Tropical Storm Sara Wind Speed Probabilities Number 13
16.11Summary for Tropical Storm Sara (AT4/AL192024)
Transportation and Logistics »
17.11V2
17.11
17.11YAMAHA
17.11 1 M
17.11
17.11 HG
17.11 S5
17.11PA Roland Rubix22 USB Audio Interface
More »